P1098: A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL)

• Daniel Hodson,
• Geoffrey Shouse,
• Ho-Jin Shin,
• Antonio Salar Silvestre,
• Sabela Bobillo Varela,
• Vincent Ribrag,
• Nicol Macpherson,
• Raul Cordoba,
• Jin Seok Kim,
• John Radford,
• Stephanie Guidez,
• Alex F. Herrera,
• Franck Morschhauser,
• Dachelle Johnson,
• Macarena Izuzquiza,
• Nisha Sambamurthy,
• Alessandra Forcina,
• Gullu Gorgun,
• Robert Chen,
• Anas Younes,
• Michael Wang,
• Wong Seog Kim

Affiliations

Daniel Hodson

1 Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Department of Haematology, The Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, United Kingdom

Geoffrey Shouse

2 City of Hope Comprehensive Cancer Center, Duarte, United States

Ho-Jin Shin

3 Pusan National University, Busan, Korea, Rep. of South

Antonio Salar Silvestre

4 Hospital del Mar, Barcelona, Spain

Sabela Bobillo Varela

5 Hospital Universitari Vall d´Hebron, Barcelona, Spain

Vincent Ribrag

6 Institut Gustave Roussy, Villejuif, France

Nicol Macpherson

7 BC Cancer - Victoria, Victoria, Canada

Raul Cordoba

8 Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain

Jin Seok Kim

9 Yonsei University College of Medicine, Seoul, Korea, Rep. of South

John Radford

10 The Christie NHS Foundation Trust, Manchester, United Kingdom

Stephanie Guidez

11 Centre Hospitalier Universitaire de Poitiers, Poitiers, France

Alex F. Herrera

2 City of Hope Comprehensive Cancer Center, Duarte, United States

Franck Morschhauser

12 Centre Hospitalier Universitaire de Lille, Lille, France

Dachelle Johnson

13 Oncology R&D, AstraZeneca, Gaithersburg, United States

Macarena Izuzquiza

14 Oncology R&D, AstraZeneca, Cambridge, United Kingdom

Nisha Sambamurthy

15 Oncology R&D, AstraZeneca, South San Francisco, United States

Alessandra Forcina

14 Oncology R&D, AstraZeneca, Cambridge, United Kingdom

Gullu Gorgun

16 Oncology R&D, AstraZeneca, Waltham, United States

Robert Chen

14 Oncology R&D, AstraZeneca, Cambridge, United Kingdom

Anas Younes

17 Oncology R&D, AstraZeneca, New York, United States

Michael Wang

18 MD Anderson Cancer Center, Houston, United States

Wong Seog Kim

19 Samsung Medical Center, Seoul, Korea, Rep. of South